Mobile Technology to Measure Knee Health in Osteoarthritis
Using Mobile Technology to Extract Mechanical Markers of Joint Health and Function in Early Knee Osteoarthritis
3 other identifiers
observational
47
1 country
1
Brief Summary
Veterans face a high prevalence of knee osteoarthritis (OA), but current diagnostic methods often miss early stages when interventions are more effective. This project will evaluate smartphone-based motion capture via OpenCap to measure joint mechanics in knee OA patients during functional activities, comparing its performance to a conventional motion capture system, patient-reported symptoms, and knee joint structure. The findings will have the potential to enable clinicians to trial OpenCap in its current form, provide insights into tracking joint health, and guide refinements to advance toward earlier diagnosis of knee OA by complementing symptom assessments with measures of joint mechanics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2026
CompletedFirst Submitted
Initial submission to the registry
April 8, 2026
CompletedFirst Posted
Study publicly available on registry
May 12, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2028
May 12, 2026
May 1, 2026
1.5 years
April 8, 2026
May 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Knee flexion angle
Knee flexion angle extracted from functional activities (e.g., walking, chair-to-stand)
Baseline and Week 1
Secondary Outcomes (1)
Knee flexion moment
Baseline and Week 1
Other Outcomes (3)
Western Ontario and McMaster Universities Osteoarthritis Index (Transformed)
Baseline and Week 1
Duration of 40-meter fast walk test
Baseline or Week 1
Repetitions for 30-second chair-to-stand test
Baseline or Week 1
Study Arms (1)
Knee OA
Adults who were previously diagnosed with early knee osteoarthritis, enrolled in Precision Assessment of Platelet Rich Plasma for Joint Preservation study (NCT03460236), and able and willing to participate in the follow-up assessment.
Eligibility Criteria
Individuals who were diagnosed with early knee osteoarthritis and had a history of being elected to receive injection treatment
You may qualify if:
- Veteran and non-Veterans
- males and females
- diagnosed with early knee osteoarthritis
- qualified for and participated in the Precision Assessment of Platelet Rich Plasma for Joint Preservation study (ClinicalTrials.gov ID: NCT03460236)
- able and willing to provide informed consent for follow-up study
You may not qualify if:
- symptomatic OA in joints other than the knee in the lower body
- joint replacement
- rheumatic disease
- BMI \> 35 kg/m\^2
- severe systematic disease defined as American Society of Anesthesiologists (ASA) 3 or above
- pregnant or intending to become pregnant during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California, 94304-1207, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jade He, PhD
VA Palo Alto Health Care System, Palo Alto, CA
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2026
First Posted
May 12, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
March 31, 2028
Last Updated
May 12, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share